Sig Sauer, faced with lawsuits over a popular pistol, gets protection in New Hampshire
Supporters in the Republican-led Legislature said the law was needed to help a major employer. The lawsuits say Sig Sauer's P320 pistol can go off without the trigger being pulled, an allegation the company denies.
The law covers all gun manufacturers and federal firearm licensees in product liability claims regarding the 'absence or presence' of four specific safety features. One of those features is an external mechanical safety that people suing Sig Sauer say should be standard on the P320, based on its design. Claims can still be filed over manufacturing defects.
Those who have sued Sig Sauer in New Hampshire and elsewhere include police, federal law enforcement officers, and other experienced gun users from multiple states who say they were wounded by the gun.
The manufacturer has prevailed in some cases. It is appealing two recent multimillion-dollar verdicts against it, in Pennsylvania and Georgia.
George Abrahams a U.S. Army veteran and painting contractor in Philadelphia who won his case, said he had holstered his P320, put it in the pocket of his athletic pants and zipped it up before going downstairs.
'All I did was come down the stairway and there was a loud explosion, and then the excruciating pain and bleeding,' he told The Associated Press in 2022. He said the bullet tore through his right thigh.
The company, which employs over 2,000 people in a state with permissive gun laws, says the P320 has internal safety mechanisms and 'has undergone the most rigorous testing and evaluation of any firearm, by military and law enforcement agencies around the world.' It says the problem is user error or incompatible holsters, not the design.
'Do you want people to be able to sue car manufacturers because they sell cars that don't have air conditioning?' state Rep. Terry Roy, a Republican from Deerfield, told the House during debate in May.
Opponents criticized the bill as a special exemption in liability law that has never been granted to any other New Hampshire company.
'I think there is a difference between helping out a large employer and creating an exemption that actually hurts people and doesn't give them their day in court,' state Rep. David Meuse, a Democrat from Portsmouth, said in an interview. His district covers Newington, where Sig Sauer is headquartered.
A 2005 federal law gives the gun industry broad legal immunity. New Hampshire was already among 32 states that have adopted gun immunity laws in some form, according to the Giffords Law Center to Prevent Gun Violence. Some states also have repealed gun industry immunity statutes or weakened them.
Sig Sauer seeks help
A Sig Sauer executive asked New Hampshire lawmakers for help in April, two weeks after a Pennsylvania-based law firm filed its most recent lawsuit in federal court in Concord on March 26 over the design of the P320. The firm represents over 100 people who have filed such lawsuits, including more than 70 in New Hampshire.
'We're fighting all these court cases out of town and every single court case we have to fight takes away money from Granite State residents and workers that we can employ and technology,' testified Bobby Cox, vice president of governmental affairs for the company.
The measure took effect once Republican Gov. Kelly Ayotte signed it on May 23. Legislators said it doesn't apply to the current lawsuits. However, lawyers for Sig Sauer mentioned it as part of their argument to dismiss the March case or break up and transfer the claims of 22 plaintiffs to court districts where they live. A hearing on the matter is set for July 21.
Ayotte's office did not respond to an AP request seeking comment, but it told The Keene Sentinel that she's 'proud to protect New Hampshire companies that create thousands of good-paying jobs from frivolous lawsuits.'
'Out-of-state trial lawyers looking to make money will not find a venue in New Hampshire,' Ayotte's office said in an emailed statement to the newspaper.
Robert Zimmerman, the plaintiffs' lead attorney in Pennsylvania, said the goal of the lawsuits is to get the weapon's design changed so that it's safe for the people who use it.
New Hampshire was the chosen location because federal rules allow lawsuits against a company in its home state, Zimmerman said. Those lawsuits have been assigned to one federal judge in Concord.
'Sig is trying to strategically decentralize this case and make every client go to 100 different courthouses and slow down the process for both sides to get a just outcome, which is a trial that is decided on the merits,' Zimmerman said in an interview.
Sig Sauer gets protection
The lawsuits accuse Sig Sauer of defective product design and marketing and negligence.
During the House debate, Roy said he owns a P320 and it's one of his favorite guns, 'but you can buy them with or without safeties.'
The plaintiffs say 'the vast majority' of P320 models sold don't come with the safety, 'even as an option.'
Sig Sauer says some users prefer the faster draw time granted by the absence of an external safety; others want the feature for added security.
Sig Sauer offered a 'voluntary upgrade' in 2017 to include an alternate design that reduces the weight of the trigger, among other features. The plaintiffs' lawyers say the upgrade did not stop unintentional discharges.
States, industries and immunity
'It's not a great look' when a manufacturer can carve out a statutory exemption for itself, but it's also not unusual, said Daniel Pi, an assistant professor at the University of New Hampshire Franklin Pierce School of Law.
In Tennessee, Gov. Bill Lee signed a bill in 2023 following a deadly school shooting that gives gun and ammunition dealers, manufacturers and sellers additional protections against lawsuits. This year, Tennessee lawmakers passed another bill to further limit liability for gun companies.
In a different industry — pesticides — governors in North Dakota and Georgia signed laws this year providing legal protections to Bayer, the maker of Roundup, a popular weed killer. Bayer has been hit with 181,000 claims alleging that the key ingredient in Roundup causes non-Hodgkin lymphoma. Bayer disputes those claims.
The Louisiana Legislature passed a bill that would protect nursing homes from most lawsuits and cap damages. Republican Gov. Jeff Landry hasn't acted on it yet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
The Open Group Launches The Open Group Open Digital Transformation™ Forum
Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio